Pharmaceutical drugs developed by two local companies received approvals in the European Union last month. On Dec. 12, Culver ...
KBRA releases its 2026 European project finance and infrastructure (PF&I) Sector Outlook, examining themes that will likely take centre stage in 2026 as well as developments and ratings trends from ...
Approval is supported by data from the DEVOTE study which showed the benefit of the SPINRAZA 50 mg and 28 mg regimen in both ...
Potential to Be the First Targeted Fast-Acting Therapy for GBS, Setting a New Standard of Care BLA Submission with U.S./European Data from ...
From Indonesia’s all-out halal regulations to sodium policies spurring rapid reformulation and taxation changes affecting ...
OS Therapies Inc. (NYSE American: OSTX) (“OS Therapies” or the “Company”), the world leader in listeria-based cancer ...
Remco Munnik, Arcana, details pharma's shift to data-first operations, AI adoption, and robust data stewardship.
KBRA releases its 2026 European project finance and infrastructure (PF&I) Sector Outlook, examining themes that will likely take centre stage in 2026 as well as developments and ratings trends from ...
France’s Ministry of the Armed Forces has taken a significant step to deepen its use of AI by awarding a framework agreement ...
Britain's medicines regulator said on Monday it was reviewing Novo Nordisk's application for an oral 25 milligram version of ...
Ocugen (OCGN) rated Buy as OCU410ST Stargardt trial advances; FDA/EMA alignment speeds path to approval. Read here for more ...
Novel immunotherapy combination regimen brings together two complementary therapies to improve outcomes for people living with multiple myeloma as early as second line1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback